Table 3.
Multivariable analysis of the differences between reclassified or not reclassified patients
| Not reclassified (n = 684) | Reclassified (n = 578) | p | Reclassification | |
|---|---|---|---|---|
| OR (95% CI), p* | ||||
| cIMT, μm | 650 ± 140 | 740 ± 140 | 0.000 | |
| Age, years | 54 ± 14 | 62 ± 9 | 0.000 | |
| Female, n (%) | 531 (78) | 437 (76) | 0.40 | |
| BMI, kg/m2 | 27 ± 6 | 28 ± 5 | 0.39 | |
| Abdominal circumference, cm | 94 ± 15 | 94 ± 14 | 0.92 | |
| Cardiovascular data | ||||
| CV risk factors, n (%) | ||||
| Current smoker | 169 (25) | 153 (26) | 0.47 | |
| Obesity | 193 (28) | 155 (27) | 0.58 | |
| Dyslipidemia | 275 (40) | 332 (57) | 0.000 | |
| Hypertension | 192 (28) | 271 (47) | 0.000 | |
| Blood pressure, mmHg | ||||
| Systolic | 130 ± 18 | 132 ± 16 | 0.024 | |
| Diastolic | 78 ± 10 | 79 ± 9 | 0.58 | |
| Lipids | ||||
| Total cholesterol, mmol/l | 5.26 ± 0.96 | 5.28 ± 0.96 | 0.66 | |
| Triglycerides, mmol/l | 1.24 ± 0.71 | 1.28 ± 0.68 | 0.35 | |
| HDL cholesterol, mmol/l | 1.58 ± 0.44 | 1.58 ± 0.44 | 0.90 | |
| LDL cholesterol, mmol/l | 3.10 ± 0.80 | 3.10 ± 0.83 | 0.94 | |
| Atherogenic index | 3.56 ± 1.11 | 3.53 ± 0.97 | 0.63 | |
| Statins, n (%) | 113 (17) | 188 (33) | 0.000 | |
| Aspirin, n (%) | 16 (2) | 27 (5) | 0.018 | |
| Antihypertensive treatment, n (%) | 140 (20) | 190 (33) | 0.000 | |
| Disease-related data | ||||
| Disease duration, years | 5 (2–12) | 5 (2–12) | 0.62 | |
| CRP at time of study, mg/l | 2.5 (0.9–6.4) | 3.0 (1.0–7.0) | 0.71 | |
| ESR at time of study, mm/ 1° hour | 11 (5 − 21) | 13 (6–25) | 0.007 | 1.00 (0.99–1.01), 0.79 |
| Rheumatoid factor, n (%) | 380 (56) | 360 (62) | 0.019 | 1.58 (1.19–2.11), 0.002 |
| ACPA, n (%) | 352 (51) | 320 (55) | 0.097 | 1.46 (1.09–1.94), 0.011 |
| DAS28-ESR | 2.96 ± 1.50 | 3.27 ± 1.46 | 0.000 | 1.09 (1.02–1.19), 0.028 |
| DAS28-PCR | 2.91 ± 1.28 | 3.10 ± 1.28 | 0.010 | 1.04 (0.93–1.16), 0.095 |
| SDAI | 3.20 ± 2.05 | 3.10 ± 2.02 | 0.73 | |
| CDAI | 8 (3–16) | 9 (4–17) | 0.078 | 1.00 (0.99–1.02), 0.52 |
| HAQ | 0.690 (0250–1.250) | 0.750 (0250–1.250) | 0.36 | |
| RAPID | 3.20 ± 2.05 | 3.10 ± 2.02 | 0.61 | |
| Current drugs, n (%) | ||||
| Prednisone | 330 (48) | 291 (50) | 0.46 | |
| Prednisone doses, mg/day | 5 (2.5–6) | 5 (5–7.5) | 0.42 | |
| NSAIDs | 282 (41) | 205 (35) | 0.036 | 0.93 (0.70–1.24), 0.62 |
| DMARDs | 525 (77) | 444 (77) | 0.98 | |
| Methotrexate | 395 (58) | 324 (56) | 0.55 | |
| Leflunomide | 70 (10) | 68 (12) | 0.39 | |
| Hydroxychloroquine | 147 (21) | 132 (23) | 0.57 | |
| Sulphasalazine | 19 (3) | 24 (4) | 0.18 | 1.69 (0.84–3.41), 0.15 |
| Anti-TNF therapy | 91 (13) | 72 (12) | 0.66 | |
| Adalimumab | 26 (4) | 28 (5) | 0.36 | |
| Infliximab | 12 (2) | 6 (1) | 0.29 | |
| Etanercept | 40 (6) | 26 (4) | 0.28 | |
| Golimumab | 1 (0) | 3 (1) | 0.34 | |
| Tocilizumab | 37 (5) | 27 (5) | 0.56 | |
| Rituximab | 9 (1) | 11 (2) | 0.40 | |
| Abatacept | 8 (1) | 13 (2) | 0.14 | 2.13 (0.77–5.97), 0.15 |
| Baricitinib | 5 (1) | 6 (1) | 0.56 | |
| Tofacitinib | 9 (1) | 5 (1) | 0.45 | |
| Historical disease-related data | ||||
| History of extraarticular manif., n (%) | 112 (16) | 119 (21) | 0.058 | 1.07 (0.75–1.52), 0.72 |
| Erosions, n (%) | 230 (34) | 216 (37) | 0.048 | 1.26 (0.93–1.72), 0.13 |
| CRP at time of disease diagnosis, mg/l | 7 (2–19) | 8 (3–22) | 0.28 | |
| CRP > 3 at time of diagnosis, n (%) | 354 (52) | 324 (56) | 0.068 | 1.13 (0.78–1.64), 0.52 |
| ESR at the time of diagnosis, mm/1st hour | 20 (11–37) | 23 (12–40) | 0.28 | |
Data represent means ± SD or median (IQR) when data were not normally distributed
CV cardiovascular, LDL low-density lipoprotein, HDL high-density lipoprotein, CRP C-reactive protein, NSAID nonsteroidal anti-inflammatory drugs, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, obesity, ESR erythrocyte sedimentation rate, BMI body mass index, DAS28 Disease Activity Score in 28 joints, ACPA anti-citrullinated protein antibodies, RAPID routine assessment of patient index, CDAI Clinical Disease Activity Index, SDAI Simple Disease Activity Index, HAQ Health Assessment Questionnaire
*Multivariable analysis is adjusted for age, dyslipidemia, hypertension, and statins and aspirin intake